Sign in
CompletedPhase 2/3

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Key facts

Who runs it
University of Utah
Where
Salt Lake City, San Francisco, Scarborough, and Washington D.C., United StatesSee the 5 sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
104 people enrolled
Started
17 Dec 2021
Ended
31 Dec 2025
Type of study
Interventional
Treatments tested
  • Single Arm
  • Neonatal Neurobehavioral Scale
Record updated
14 July 2026

Who can take part

Age
0 years to 52 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Pregnant women 18 years of age and over with a singleton fetus with known or suspected congenital heart disease anticipated to need intervention or surgery within 30 days of birth

Who cannot take part

  • Fetal extra-cardiac anomalies
  • Known fetal chromosomal or genetic abnormalities
  • Multiple gestation pregnancy

Where in United States

  • Primary Children's HospitalSalt Lake City, United States
  • University of UtahSalt Lake City, United States
  • University of California San FranciscoSan Francisco, United States
  • Maine Medical CenterScarborough, United States
  • Children's National Medical CenterWashington D.C., United States

About the trial

What the trial wants to find out

Determine 1) the impact of abnormal fetal cerebrovascular physiology with neurodevelopmental delay (ND) outcomes and 2) how this relationship is modified by patient and environmental factors such as chronic congenital heart disease (CCHD) lesion, maternal-fetal environment, and social determinants of heath (SDOH) in a diverse population using a multicenter design.

Read full original descriptionShow less

Pregnant women will be approached during one of their fetal cardiology clinic visits.

The group in the trial

  • Single ArmTreatment being tested

    Maternal Hyperoxia (MH) will be administered to pregnant patients after their standard of care fetal echocardiogram has been performed at their scheduled fetal cardiology visit at ³28 weeks gestation. The evaluation at ³28 weeks was chosen since gestational age impacts both the cardiovascular and cerebrovascular response to MH.31 The evaluation will extend the duration of the visit by approximately 30 minutes but additional evaluations or visits for the study will not be required.

    Treatment: Single Arm and Neonatal Neurobehavioral Scale

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
14 July 2026